English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
 Local TagsRelease HistoryDetailsSummary
  The antitumor efficacy of monomeric disintegrin obtustatin in S-180 sarcoma mouse model

Ghazaryan, N., Movsisyan, N., Macedo, J. C., Vaz, S., Ayvazyan, N., Pardo, L., et al. (2019). The antitumor efficacy of monomeric disintegrin obtustatin in S-180 sarcoma mouse model. Invest New Drugs, 37(5), 1044-1051. doi:10.1007/s10637-019-00734-2.

Item is

 

show all hide all

Basic

show hide
Item Permalink: https://hdl.handle.net/21.11116/0000-0009-F257-4 Version Permalink: https://hdl.handle.net/21.11116/0000-0009-F258-3
Genre: Journal Article

Files

show Files

Locators

show
hide
Locator:
https://www.ncbi.nlm.nih.gov/pubmed/30680583 (Any fulltext)
Description:
-
OA-Status:

Creators

show
hide
 Creators:
Ghazaryan, N.1, Author
Movsisyan, N.1, Author
Macedo, J. C.1, Author
Vaz, S.1, Author
Ayvazyan, N.1, Author
Pardo, L.1, Author
Logarinho, E.1, Author
Affiliations:
1Max Planck Society, ou_persistent13              

Content

show
hide
Free keywords: Angiogenesis Obtustatin Sarcoma Vegf
 Abstract: Obtustatin, isolated from the Levantine Viper snake venom (Macrovipera lebetina obtusa -MLO), is the shortest known monomeric disintegrin shown to specifically inhibit the binding of the alpha1beta1 integrin to collagen IV. Its oncostatic effect is due to the inhibition of angiogenesis, likely through alpha1beta1 integrin inhibition in endothelial cells. To explore the therapeutic potential of obtustatin, we studied its effect in S-180 sarcoma-bearing mice model in vivo as well as in human dermal microvascular endothelial cells (HMVEC-D) in vitro, and tested anti-angiogenic activity in vivo using the chick embryo chorioallantoic membrane assay (CAM assay). Our in vivo results show that obtustatin inhibits tumour growth by 33%. The expression of vascular endothelial growth factor (VEGF) increased after treatment with obtustatin, but the level of expression of caspase 8 did not change. In addition, our results demonstrate that obtustatin inhibits FGF2-induced angiogenesis in the CAM assay. Our in vitro results show that obtustatin does not exhibit cytotoxic activity in HMVEC-D cells in comparison to in vivo results. Thus, our findings disclose that obtustatin might be a potential candidate for the treatment of sarcoma in vivo with low toxicity.

Details

show
hide
Language(s):
 Dates: 2019-01-252019-01-27
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: Other: 30680583
DOI: 10.1007/s10637-019-00734-2
ISSN: 1573-0646 (Electronic) 0167-6997 (Linking)
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Invest New Drugs
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 37 (5) Sequence Number: - Start / End Page: 1044 - 1051 Identifier: -